The Current Developments in Medicinal Plant Genomics Enabled the Diversification of Secondary Metabolites’ Biosynthesis

Mohammad Murtaza Alami, Zhen Ouyang, Yipeng Zhang, Shaohua Shu, Guozheng Yang, Zhinan Mei, Xuekui WangInternational Journal of Molecular Sciences 2022 · DOI

TL;DR

This review highlights how advancements in medicinal plant genomics, particularly whole-genome sequencing and multi-omics approaches, are revolutionizing our understanding of how these plants produce diverse secondary metabolites. This knowledge is crucial for unlocking the potential of medicinal plants for drug discovery and traditional medicine.

What Problem Does This Paper Address?

Medicinal plants are a treasure trove of compounds with therapeutic and industrial applications. However, the low natural concentration of many of these valuable secondary metabolites, coupled with a limited understanding of their complex biosynthetic pathways and genetic regulation, has historically hindered their efficient production and utilization. This paper addresses the need for a comprehensive overview of how modern genomic and multi-omics technologies are overcoming these challenges, enabling researchers to delve into the genetic underpinnings of secondary metabolite biosynthesis in medicinal plants.

Methods

The paper emphasizes the application of a suite of powerful "omics" technologies:

  • Genomics: Whole-genome sequencing (including third-generation technologies like PacBio and Nanopore) is the foundation, providing the blueprint of medicinal plants.
  • Transcriptomics (RNA-Seq): This technique measures gene expression levels, revealing which genes are active and potentially involved in metabolite production under specific conditions.
  • Proteomics: This approach identifies and quantifies proteins, offering insights into the functional machinery of the cell and the enzymes driving metabolic pathways.
  • Metabolomics: This technique profiles the small molecules (metabolites) produced by the plant, directly revealing the end products of biosynthetic pathways.

The paper also discusses comparative genomics to understand evolutionary relationships and gene family expansions, and the role of polyploidy (whole-genome duplication) in diversifying metabolic capabilities. Furthermore, it introduces Metabolite-based, Genome-Wide Association Studies (mGWAS) and Metabolic Quantitative Trait Loci (mQTL) mapping as tools to link genetic variations to specific metabolite variations. Weighted Gene Co-Expression Network Analysis (WGCNA) is highlighted for identifying co-regulated genes involved in metabolic pathways.

Datasets

The paper does not focus on specific datasets for training or evaluation but rather reviews existing literature and highlights the application of these omics techniques across numerous medicinal plant species. It references supplementary tables (S1-S3) that list completed plant genomics projects.

Key Insights and Ideas

  • Genomics as a Game Changer: The dramatic decrease in sequencing costs and the advancement of sequencing technologies have made high-quality genome sequencing of medicinal plants feasible, laying the groundwork for in-depth molecular research.
  • Multi-omics Synergy: Integrating data from genomics, transcriptomics, proteomics, and metabolomics provides a holistic view, allowing researchers to connect genes to their functional products and ultimately to the metabolites they produce. This is crucial for deciphering complex biosynthetic pathways.
  • Polyploidy as a Driver of Diversity: Whole-genome duplication events have played a significant role in the evolution of medicinal plants, leading to gene family expansion and the diversification of secondary metabolite production, contributing to unique plant traits and adaptations.
  • Unlocking Biosynthetic Gene Clusters (BGCs): Multi-omics approaches are instrumental in identifying BGCs, which are groups of genes that work together to produce specific secondary metabolites.
  • Bridging Traditional Medicine and Modern Science: By elucidating the genetic basis of secondary metabolite production, these advancements can accelerate the discovery of new plant-based drugs and validate traditional medicinal practices.

Key Results

The paper doesn't present novel experimental results but rather synthesizes findings from numerous studies. Key outcomes highlighted include:

  • Identification of specific genes encoding enzymes involved in the biosynthesis of various secondary metabolites (e.g., (S)-canadine synthase in Coptis chinensis, CYP719 gene, cytochrome P450 genes in Salvia miltiorrhiza).
  • Elucidation of evolutionary pathways and diversification of secondary metabolite biosynthesis through comparative genomics and polyploidy analysis.
  • Demonstration of how multi-omics approaches can accelerate the discovery of candidate genes for metabolic engineering and heterologous bioproduction.
  • Table 1 and Table 2 provide extensive lists of medicinal plants, sequencing technologies used, identified genes, and the corresponding biosynthetic pathways and references, showcasing the breadth of recent research.

Limitations and Future Work

The authors acknowledge that while significant progress has been made, the application of some advanced genomic tools like mQTL, BSA, WGCNA, and mGWAS in medicinal plants is still nascent and requires further strengthening. They emphasize the need for continued research to fully understand the complex genetic regulation of secondary metabolite biosynthesis. Future work should focus on:

  • Further application and refinement of multi-omics approaches for comprehensive analysis.
  • Continued genome sequencing of diverse medicinal plant species.
  • Leveraging these genomic resources for metabolic engineering and the development of novel plant-based drugs and therapies.
  • Strengthening the understanding of the evolutionary history and diversification of secondary metabolite pathways.

Summary updated

Abstract

Medicinal plants produce important substrates for their adaptation and defenses against environmental factors and, at the same time, are used for traditional medicine and industrial additives. Plants have relatively little in the way of secondary metabolites via biosynthesis. Recently, the whole-genome sequencing of medicinal plants and the identification of secondary metabolite production were revolutionized by the rapid development and cheap cost of sequencing technology. Advances in functional genomics, such as transcriptomics, proteomics, and metabolomics, pave the way for discoveries in secondary metabolites and related key genes. The multi-omics approaches can offer tremendous insight into the variety, distribution, and development of biosynthetic gene clusters (BGCs). Although many reviews have reported on the plant and medicinal plant genome, chemistry, and pharmacology, there is no review giving a comprehensive report about the medicinal plant genome and multi-omics approaches to study the biosynthesis pathway of secondary metabolites. Here, we introduce the medicinal plant genome and the application of multi-omics tools for identifying genes related to the biosynthesis pathway of secondary metabolites. Moreover, we explore comparative genomics and polyploidy for gene family analysis in medicinal plants. This study promotes medicinal plant genomics, which contributes to the biosynthesis and screening of plant substrates and plant-based drugs and prompts the research efficiency of traditional medicine.
BibTeX
@article{alami2022current,
  author = {Mohammad Murtaza Alami and Zhen Ouyang and Yipeng Zhang and Shaohua Shu and Guozheng Yang and Zhinan Mei and Xuekui Wang},
  title = {{The Current Developments in Medicinal Plant Genomics Enabled the Diversification of Secondary Metabolites’ Biosynthesis}},
  journal = {International Journal of Molecular Sciences},
  year = {2022},
  doi = {10.3390/ijms232415932},
}
Figure